China Resources Pharmaceutical's (HKG:3320) attributable profit fell to 3.35 billion yuan in 2024 from 3.85 billion yuan in 2023, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share at the drug company decreased to 0.53 yuan from 0.61 yuan in the previous year.
Revenue grew to 257.7 billion yuan from 244.7 billion yuan a year earlier.
The company declared a final dividend of 0.052 yuan per share, payable July 14 to shareholders on record as of June 2.
Shares fell 4% during Wednesday's afternoon trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。